Zobrazeno 1 - 10
of 546
pro vyhledávání: '"Daniel P, Petrylak"'
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-15 (2023)
Abstract Bladder cancer (BC) is one of the most prevalent malignancies worldwide and FGFR3 alterations are particularly common in BC. Despite approval of erdafitinib, durable responses for FGFR inhibitors are still uncommon and most patients relapse
Externí odkaz:
https://doaj.org/article/ad2900efad9142f190ef3474f893fd53
Autor:
Nobuaki Matsubara, Junji Yonese, Takahiro Kojima, Haruhito Azuma, Hiroaki Matsumoto, Thomas Powles, Jonathan E. Rosenberg, Daniel P. Petrylak, Maria Matsangou, Chunzhang Wu, Mary Campbell, Mayumi Yamashiro
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 2761-2771 (2023)
Abstract Background Enfortumab vedotin (EV) is an antibody‐drug conjugate showing significant overall survival (OS) benefit versus chemotherapy for patients with previously treated locally advanced or metastatic urothelial carcinoma (la/mUC) in EV
Externí odkaz:
https://doaj.org/article/402416e25b934d6ba8bab3a603b2623e
Autor:
Tian Zhang, Nicholas J Vogelzang, Daniel P Petrylak, Ravi A Madan, Karen A Autio, Ray Li, Helen Cho, Szu-Yu Tang, Celestia S Higano, Luke Nordquist, Leonard J Appleman, Xin-Hua Zhu, Hani Babiker, Sandip M Prasad, Michael T Schweizer, Stephane Billotte, Nora Cavazos, Orlaith Bogg, Kam Chan, Megan Kaneda, I-Ming Wang, Jenny Zheng, Robert Hollingsworth, Kenneth A Kern
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Background This phase 1 study evaluated PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in two clinical states of prostate cancer (PC), metastatic castration-resistant PC (mCRPC) and biochemical recurrence (BCR).Methods For dose escal
Externí odkaz:
https://doaj.org/article/a4a8a3a078ab4567a1641ae4c2b5d1db
Autor:
Jun Li, Stefanie Zschäbitz, Daniel P Petrylak, Margitta Retz, Prabhu Bhagavatheeswaran, Marc-Oliver Grimm, Jose Perez-Gracia, Gwenaelle Gravis, Karim Fizazi, Jeffrey C Goh, Mauricio Burotto, Daniel Castellano, Fred Saad, Andrew J Armstrong, HAKIM MAHAMMEDI, Russell K Pachynski, Louis Lacombe, Diogo Assed Bastos, Steven L McCune, Juan Carlos Vázquez Limón, Edmond M Kwan, Aude Fléchon, David R Shaffer, Neha P Amin, Keziban Ünsal-Kaçmaz, Xuya Wang, Andrea Loehr
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 8 (2022)
Background CheckMate 9KD (NCT03338790) is a non-randomized, multicohort, phase 2 trial of nivolumab plus other anticancer treatments for metastatic castration-resistant prostate cancer (mCRPC). We report results from cohorts A1 and A2 of CheckMate 9K
Externí odkaz:
https://doaj.org/article/47bed5baf90f4a54860bcc0aa14ca352
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundThe poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib was approved in the United States based on the phase 2 TRITON2 study of patients with BRCA1 or BRCA2 (BRCA)–mutated metastatic castration-resistant prostate cancer (mCRPC). Althou
Externí odkaz:
https://doaj.org/article/65957296af2d4cf89f86adf078de7ca7
Autor:
Andrea Necchi, Hiroyuki Nishiyama, Nobuaki Matsubara, Jae-Lyun Lee, Daniel P. Petrylak, Ronald de Wit, Alexandra Drakaki, Astra M. Liepa, Huzhang Mao, Katherine Bell-McGuinn, Thomas Powles
Publikováno v:
BMC Urology, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background To evaluate patient-reported outcomes with ramucirumab plus docetaxel, a regimen which improved progression-free survival in platinum-refractory advanced urothelial carcinoma (aUC). Methods RANGE—a randomized, double-blinded, ph
Externí odkaz:
https://doaj.org/article/4a6e35606be743dd920d27ac9dcff020
Autor:
Emmanuel S. Antonarakis, Sumit K. Subudhi, Christopher M. Pieczonka, Lawrence I. Karsh, David I. Quinn, Jason M. Hafron, Helen M. Wilfehrt, Matthew Harmon, Nadeem A. Sheikh, Neal D. Shore, Daniel P. Petrylak
Publikováno v:
Clinical Cancer Research. :OF1-OF9
Purpose: We present long-term outcomes from 2 randomized studies [STAMP (with abiraterone, NCT01487863) and STRIDE (with enzalutamide, NCT01981122)] that were performed to study the impact of sequential or concurrent administration of androgen recept
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49cdd98fb625c847e5a796dc494acd31
https://doi.org/10.1158/1078-0432.ccr-22-3832
https://doi.org/10.1158/1078-0432.ccr-22-3832
Autor:
Susan Halabi, Qian Yang, Akash Roy, Bin Luo, John C. Araujo, Christopher Logothetis, Cora N. Sternberg, Andrew J. Armstrong, Michael A. Carducci, Kim N. Chi, Johann S. de Bono, Daniel P. Petrylak, Karim Fizazi, Celestia S. Higano, Michael J. Morris, Dana E. Rathkopf, Fred Saad, Charles J. Ryan, Eric J. Small, William Kevin Kelly
Publikováno v:
Journal of Clinical Oncology. 41:2736-2746
PURPOSE We have previously developed and externally validated a prognostic model of overall survival (OS) in men with metastatic, castration-resistant prostate cancer (mCRPC) treated with docetaxel. We sought to externally validate this model in a br
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b75c9bc15ead7c9b9ae0574de91963f0
https://doi.org/10.1200/jco.22.02661
https://doi.org/10.1200/jco.22.02661
Autor:
Cora N. Sternberg, Daniel P. Petrylak, Joaquim Bellmunt, Hiroyuki Nishiyama, Andrea Necchi, Howard Gurney, Jae-Lyun Lee, Michiel S. van der Heijden, Eli Rosenbaum, Nicolas Penel, See-Tong Pang, Jian-Ri Li, Xavier García del Muro, Florence Joly, Zsuzsanna Pápai, Weichao Bao, Peter Ellinghaus, Chengxing Lu, Mitchell Sierecki, Sabine Coppieters, Keiko Nakajima, Tatiane Cristine Ishida, David I. Quinn
Publikováno v:
Journal of Clinical Oncology. 41:629-639
PURPOSE Rogaratinib, an oral pan-fibroblast growth factor receptor (FGFR1-4) inhibitor, showed promising phase I efficacy and safety in patients with advanced urothelial carcinoma (UC) with FGFR1-3 mRNA overexpression. We assessed rogaratinib efficac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc755d9c3cfa6ea9c4e87d64f27f4dcc
https://doi.org/10.1200/jco.21.02303
https://doi.org/10.1200/jco.21.02303
Autor:
Serhan Ünlü, Junghee Jenny Shin, Jennefer Par-Young, Michael Simonov, Joseph Vinetz, Daniel P. Petrylak, Insoo Kang, Joseph W. Kim
Publikováno v:
Cancer Investigation. 41:77-83
TMPRSS2 is utilized by SARS-CoV-2 for cellular entry. Androgen-Androgen receptor directed therapy (A/ARDT) downregulates expression of TMPRSS2. We hypothesized A/ARDT might protect prostate cancer (PCa) patients from poor COVID-19 outcome. A retrospe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c124e8f3f31df7d6372acea2425403b3
https://doi.org/10.1080/07357907.2022.2139839
https://doi.org/10.1080/07357907.2022.2139839